Literature DB >> 20351457

In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones.

Carlos Hernan Rodriguez1, Alejandra De Ambrosio, Milena Bajuk, Mariela Spinozzi, Marcela Nastro, Karina Bombicino, Marcela Radice, Gabriel Gutkind, Carlos Vay, Angela Famiglietti.   

Abstract

BACKGROUND: Multidrug-resistant strains of Acinetobacter baumannii have been reported increasingly around the world. The administration of an association of antibiotics has been proposed to create an active combination and to prevent the emergence of resistance.
METHODOLOGY: The activity of colistin, rifampicin, gentamicin, imipenem and their associations was evaluated by means of killing curves in fourteen isolates belonging to three endemic PFGE types, in a university hospital of Buenos Aires city. The 14 isolates were selected on the basis of different mechanisms responsible for resistance to carbapenems and different susceptibility to colistin.
RESULTS: The mechanism responsible for the resistance to imipenem was the production of OXA-23 and OXA-58 carbapenemases. Heteroresistance to colistin was observed in six isolates. The associations colistin-rifampicin and colistin-imipenem were synergistic in heteroresistant isolates and prevented the development of colistin-resistant mutants. The association imipenem-gentamicin was bactericidal in gentamicin susceptible isolates, whereas the association imipenem-rifampicin was always indifferent.
CONCLUSION: The antimicrobial activity and the presence of synergy are related to the antimicrobials' susceptibilities irrespective of the PFGE type or the OXA-carbapenemase produced.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20351457     DOI: 10.3855/jidc.604

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  12 in total

1.  Task force on management and prevention of Acinetobacter baumannii infections in the ICU.

Authors:  José Garnacho-Montero; George Dimopoulos; Garyphallia Poulakou; Murat Akova; José Miguel Cisneros; Jan De Waele; Nicola Petrosillo; Harald Seifert; Jean François Timsit; Jordi Vila; Jean-Ralph Zahar; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2015-10-05       Impact factor: 17.440

2.  Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections.

Authors:  Eszter Ostorhazi; Ferenc Rozgonyi; Andras Sztodola; Ferenc Harmos; Ilona Kovalszky; Dora Szabo; Daniel Knappe; Ralf Hoffmann; Marco Cassone; John D Wade; Robert A Bonomo; Laszlo Otvos
Journal:  J Antimicrob Chemother       Date:  2010-09-01       Impact factor: 5.790

Review 3.  Carbapenems: past, present, and future.

Authors:  Krisztina M Papp-Wallace; Andrea Endimiani; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

4.  Activity of the colistin-rifampicin combination against colistin-resistant, carbapenemase-producing Gram-negative bacteria.

Authors:  Marcela Nastro; Carlos Hernan Rodríguez; Renata Monge; Jonathan Zintgraff; Liliana Neira; Mirta Rebollo; Carlos Vay; Angela Famiglietti
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

Review 5.  In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.

Authors:  Stamatis Karakonstantis; Petros Ioannou; Diamantis D Kofteridis
Journal:  Infection       Date:  2022-01-04       Impact factor: 3.553

Review 6.  Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems.

Authors:  Oren Zusman; Tomer Avni; Leonard Leibovici; Amos Adler; Lena Friberg; Theodouli Stergiopoulou; Yehuda Carmeli; Mical Paul
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

7.  Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients.

Authors:  Wang Liang; Xiao-Fang Liu; Jun Huang; De-Mei Zhu; Jian Li; Jing Zhang
Journal:  BMC Infect Dis       Date:  2011-04-27       Impact factor: 3.090

8.  In vitro and in vivo analysis of antimicrobial agents alone and in combination against multi-drug resistant Acinetobacter baumannii.

Authors:  Songzhe He; Hui He; Yi Chen; Yueming Chen; Wei Wang; Daojun Yu
Journal:  Front Microbiol       Date:  2015-05-27       Impact factor: 5.640

Review 9.  Synergistic Effect of Colistin and Rifampin Against Multidrug Resistant Acinetobacter baumannii: A Systematic Review and Meta-Analysis.

Authors:  Maryam Mohammadi; Hatef Khayat; Koroush Sayehmiri; Setareh Soroush; Fatemeh Sayehmiri; Somayeh Delfani; Lidija Bogdanovic; Morovat Taherikalani
Journal:  Open Microbiol J       Date:  2017-04-28

Review 10.  Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options.

Authors:  Chang-Ro Lee; Jung Hun Lee; Moonhee Park; Kwang Seung Park; Il Kwon Bae; Young Bae Kim; Chang-Jun Cha; Byeong Chul Jeong; Sang Hee Lee
Journal:  Front Cell Infect Microbiol       Date:  2017-03-13       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.